Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010, 154(4):355-361 | DOI: 10.5507/bp.2010.053

AUGMENTATION OF ANTIDEPRESSANTS WITH BRIGHT LIGHT THERAPY IN PATIENTS WITH COMORBID DEPRESSION AND BORDERLINE PERSONALITY DISORDER

Jan Prasko*a,b,c,d, Martin Brunovskyc,d, Klara Latalovaa,b, Ales Grambala,b, Michal Raszka*c,d, Jana Vyskocilovac, Lucie Zavesickac,d
a Department of Psychiatry, University Hospital Olomouc, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic
b Psychiatry Clinic, Faculty of Medicine and Dentistry, Palacky University Olomouc
c Prague Psychiatric Centre, Ustavni 91, Prague 8
d Centre of Neuropsychiatric Studies, Ustavni 91, Prague 8

Backround. Borderline personality disorder (BPD) is typically characterized by instability and impairmed behaviour, affectivity, interpersonal relations and lifestyle. The most common condition comorbid with BPD is a depressive episode. Depression is associated with severe disturbance of the circadian rhythms. This is apparent in depressive patients with BPD. Both sleep and diurnal rhythms are disturbed and the symptoms fluctuate. Bright light may be an effective in treatment of seasonal affective disorder, circadian sleep disorder and jet lag. It also improves sleep-wake patterns and behavioural disorders in hospitalized patients with Alzheimer's disease. Several studies have suggested antidepressant effects of phototherapy in non-seasonal depressive episodes. The treatment of comorbid depressive disorder and borderline personality disorder (BPD) is usually reported to be less successful than the treatment of patients without personality disorder. Studies describing the use of bright light in depressed patients with comorbid BPD have not been published so far.

Method: The aim of this open study was to assess the effectiveness of a 6-week combined therapy with the application of bright light (10,000 lux, 6:30 to 7:30 a.m. for 6 weeks) added to SSRIs in drug-resistant depressed patients with comorbid BPD who did not respond with improvement to 6-week administration of antidepressants. The study comprised 13 female patients who met the ICD-10 diagnostic criteria for research and the DSM-IV-TR diagnostic criteria for major depression. The participants were regularly evaluated using the CGI, HAMD and MADRS scales and the BDI and BDI self-report inventories.

Results: According to all the assessment instruments, the application of bright white light leads to a significant improvement. However, the results must be interpreted with caution due to the open nature of the study.

Keywords: Bright light therapy, Non-seasonal depressive disorder, Depressive episode, Resistance to therapy, Borderline personality disorder, Comorbidity, Open study

Received: March 15, 2010; Accepted: April 16, 2010; Published: December 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Prasko, J., Brunovsky, M., Latalova, K., Grambal, A., Raszka, M., Vyskocilova, J., & Zavesicka, L. (2010). AUGMENTATION OF ANTIDEPRESSANTS WITH BRIGHT LIGHT THERAPY IN PATIENTS WITH COMORBID DEPRESSION AND BORDERLINE PERSONALITY DISORDER. Biomedical papers154(4), 355-361. doi: 10.5507/bp.2010.053
Download citation

References

  1. Phillips KA and Gunderson JG. Personality disorders, in The American Psychiatric Press Textbook of Psychiatry, 3rd ed. Edited by Hales RE, Yudofsky SC, Talbott JA. American Psychiatric Press, Washington DC 1999; 795823.
  2. Corbitt EM and Widiger TA. Sex differences among the personality disorder. An exploration of the data. Clin Psychol Sci Pract 1995; 2:225238. Go to original source...
  3. Linehan MM and Kehrer CA. Borderline personality disorder. In: Barlow, D.H. (ed.): Clinical handbook of psychological disorders. A step-by-step treatment manual. The Guilford Press, New York 1993; 396441.
  4. Markowitz P. Pharmacotherapy of impulsivity, aggression, and related disorders, in Impulsivity and Aggression. Edited by Hollander E, Stein DJ. New York, John Wiley & Sons 1995; 263287.
  5. Siever LJ. Evaluation framework for biological correlates of personality disorder. Psychiatr Times 1990; 7:1719.
  6. Silk KR. Borderline personality disorder. Overview of biological factors. Psychiatr Clin N Am 2000; 23:6175. Go to original source... Go to PubMed...
  7. Gunderson JG. Borderline Personality Disorder: A Clinical Guide. American Psychiatric Press, Washington DC 2001. Go to original source...
  8. American Psychiatric Association: Practice Guidelines for the Treatment of Patients with Borderline Personality Disorder. Washington, DC, APA 2001.
  9. Markowitz P. Pharmacotherapy. In: Livesley WJ (ed): Handbook of Personality Disorders. Guilford Press, New York 2001; 475493.
  10. Praško J, Herman E, Horáček J et al. Poruchy osobnosti. Praha: Portál 2003; 360p.
  11. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:2329. Go to original source... Go to PubMed...
  12. Markowitz PJ, Calabrese JR, Charles SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:10641067. Go to original source...
  13. Markowitz PJ and Wagner C. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31:773 777.
  14. Cornelius JR, Soloff PH, Perel JM et al. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26:151154.
  15. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55:137141.
  16. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:885893. Go to original source... Go to PubMed...
  17. Praško J, Horáček J, Klaschka J et al. Bright light therapy and/or imipramine for inpatients with recurrent non seasonal depression. Neuro Endocrinol Lett 2002; 23:109113.
  18. Illnerová H, Borbély AA, Wirz-Justice A, Praško J. Circadian rhythmicity: from basic science to clinical approach. Suppl Clin Neurophysiol 2000; 53:339347. Go to original source...
  19. Praško J, Houbová P, Novák T, Záleský R, Espa-Červená K, Pašková B, Vyskočilová J. Influence of personality disorder on the treatment of panic disorder - comparison study. Neuro Endocrinol Lett 2005; 26:667674.
  20. Lecrubier Y, Sheehan DV, Weiller E et al. The MINI-international neuropsychiatric interview (M.I.N.I.): a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997; 12:224231. Go to original source... Go to PubMed...
  21. Guy W (ed.). ECDEU Assessment manual for psychopharmacology. Rockville, U.S. DHEW 1976. Go to original source...
  22. Hamilton M. Development of a Rating Scale for Primary Depressive Illness. Brit J Soc Clin Psychol 1967; 6:278296. Go to original source... Go to PubMed...
  23. Montgomery SA, Asberg M. A New Depression Scale Designed to be Sensitive to Change. Brit J Psychiatry 1979; 134:382389. Go to original source... Go to PubMed...
  24. Beck AT and Beamesderfer A. Assessment of Depression: The Depression Inventory. In: Psychological Measurements in Psychopharmacology 1974; 7:151169. Go to original source...
  25. Beck AT and Emery G. Anxiety disorders and phobias: A cognitive perspective. New York, Basic Books 1985.
  26. Eastman C. What the placebo literature can tell us about phototherapy for SAD. Psychopharmacol Bull 1990; 26:495504. DOI: 10.1097/00004714-199502000-00005 Go to original source... Go to PubMed...